4D pharma to Participate at the Chardan Metagenomics and Microbiome Medicines Summit

4D pharma to Participate at the Chardan Metagenomics and Microbiome Medicines Summit
4D pharma announces FDA clearance of IND application for Live Biotherapeutics MRx0005 and MRx0029 for the treatment of Parkinson’s disease
4D pharma to Restate Unaudited Interim Financial Statements for the Six-Month Period Ended June 30, 2021 to Correct Accounting for Warrants
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection includes Audioboom, Cloudbreak, Cobra, Cizzle, Caracal, Ixico, Kibo, Live,
Zak Mir takes a charting look at some of the most followed small caps. Today’s selection includes Alba, Arrow, Atlantic, Cobra, Deltic, Empire, Live, Omega, Predator, Petrotal, Premier.
A company which some in the market are suggesting could be bigger than Greatland Gold (GGP), Artemis Resources (ARV), said that exploration drilling has commenced at the Chapman Discovery, part
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection includes African Pioneer, Beowulf Mining, Cyba, Eurasia, GCM, Ixico,
Leeds, UK, January 4, 2022, – 4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic Products (LBPs), a novel class of drug derived
Zak Mir takes a technical perspective on some of the most followed small caps on the London market. Today’s selection includes Blue, Challenger, Eve, Feedback, Hemo, Live, Midatech, MyHealth, Nanosynth,
4D pharma announces positive topline results from Part A of Phase I/II trial of MRx-4DP0004 for the treatment of asthma
4D pharma presents microbiome analyses from Phase II clinical trial of Blautix® for IBS-C and IBS-D at Gastro 2021